After manufacturing issues led ADMA Biologics to pull its primary immune deficiency disease drug Bivigam from the market, it's won a new FDA approval.
With an Ebola outbreak in Congo outrunning vaccination efforts, the WHO wants to use an experimental drug from Johnson & Johnson.
With FDA approval of Zolgensma expected soon, Novartis CEO Vasant Narasimhan is confident that the company's manufacturing network will meet demand.
Novartis may be struggling a bit in the U.S. with cancer drug launches, but it has a new market it can now explore: Saudi Arabia.
Merck & Co., which has been riding a wave of Gardasil sales, will invest $1 billion and add 100 jobs to expand production.
Lenders have put Akorn on a short leash while they negotiate a new loan agreement, but improvements in finances and manufacturing have been made.
Drug distributor McKesson, which has had serious opioid habits, has settled another lawsuit tying it to the nation’s opioid problems.
India’s Cadila found a ray of sunshine in the fact that the FDA issued 14 observations during an inspection of its formulation plant in Moraiya.
The U.S. is seeing a spike in measles cases, but Merck, the sole producer of the measles vaccine for the U.S., says it has production in hand.
Heron Therapeutics has received a complete response letter for its pain drug candidate because the FDA had issues about CMC processes.